Alerts will be sent to your verified email
Verify Email
VIVIMEDLAB
|
Vivimed Labs
|
JFL Life Sciences
|
Murae Organisor
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
API Sector
|
|||
|
US DMF Filings
|
150.0 . | n/a | n/a |
|
Pharmaceutical Sector
|
|||
|
R&D as a % of Total Sales
|
0.14 % | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
-175.12 % | 11.5 % | 7.44 % |
|
5yr average Equity Multiplier
|
7.33 | 3.23 | 1.97 |
|
5yr Average Asset Turnover Ratio
|
0.42 | 0.95 | 0.85 |
|
5yr Avg Net Profit Margin
|
-43.68 % | 4.98 % | 5.88 % |
|
Price to Book
|
0.23 | 0.0 | 0.43 |
|
P/E
|
0.0 | 18.6 | 19.6 |
|
5yr Avg Cash Conversion Cycle
|
397.97 Days | 217.93 Days | 3241.06 Days |
|
Inventory Days
|
238.36 Days | 85.64 Days | 515.14 Days |
|
Days Receivable
|
160.14 Days | 186.74 Days | 1372.66 Days |
|
Days Payable
|
116.96 Days | 98.82 Days | 17.5 Days |
|
5yr Average Interest Coverage Ratio
|
-1.57 | 3.02 | 11.0 |
|
5yr Avg ROCE
|
-10.07 % | 18.94 % | 12.76 % |
|
5yr Avg Operating Profit Margin
|
-16.03 % | 9.53 % | -13.99 % |
|
5 yr average Debt to Equity
|
2.7 | 1.19 | 0.48 |
|
5yr CAGR Net Profit
|
n/a | 55.85 % | -51.27 % |
|
5yr Average Return on Assets
|
-9.33 % | 4.15 % | 4.01 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
20.94 % | 67.47 % | 0.0 |
|
Share Pledged by Promoters
|
37.06 % | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-11.85 % | 0.0 | -50.21 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Vivimed Labs
|
JFL Life Sciences
|
Murae Organisor
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
-
|
-
|
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
-
|
-
|
|
Capex
|
Capex
|
-
|
-
|
|
Asset Break-Up
|
Asset Break-Up
|
-
|
-
|